HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Belite Bio (NASDAQ:BLTE) and raised the price target from $59 to $60.
August 13, 2024 | 6:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Belite Bio (NASDAQ:BLTE) and raised the price target from $59 to $60.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive short-term price appreciation for Belite Bio.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100